The MDA-Thai FDA Reliance Programme Is Now Fully Live: What Foreign Manufacturers Need to Do with It

On May 1, 2026, the Medical Device Authority of Malaysia and the Thai Food and Drug Administration jointly announced the full implementation of the MDA-Thai FDA Medical Device Regulatory Reliance Programme. The three-month pilot phase, which ran from February 1 to April 30, confirmed that the model works in practice. Full implementation is now in effect, with no expiry date announced. For foreign manufacturers who hold or are pursuing registration in both markets, this changes the calculus on Thai market entry significantly, and the window to use it strategically is open right now.

What the Programme Does

Regulatory reliance means one authority accepts and builds on the regulatory review already completed by another, rather than conducting a full independent evaluation from scratch. In practical terms, for a medical device already registered with Malaysia's MDA, the Thai FDA's most time-consuming step, the external expert evaluation, is removed from the process under this programme.

The programme operates in both directions. A Thai FDA-approved device can use the MDA's Verification Route in Malaysia, which reduces the MDA review from the standard 60 working days to approximately 30 days. In the direction most relevant to foreign manufacturers entering Thailand, a device with valid MDA Malaysia approval can enter Thailand under the Thai FDA reliance route, bypassing the external expert evaluation that would otherwise be required for a full CSDT submission.

The underlying principle is Good Reliance Practices, a framework developed through the Global Harmonization Working Party and increasingly adopted across ASEAN. The Thai FDA's participation as a trusted reference authority in ASEAN sits alongside Singapore's HSA, which was already recognised as a reference authority by multiple regulators. The MDA-Thai FDA programme now formalises bilateral reliance at a level of specificity that makes it operationally useful, not just a diplomatic statement.

Which Devices and Manufacturers Qualify

The programme covers Class B, C, and D devices under MDA Malaysia's classification, which corresponds to Class 2, 3, and 4 under Thai FDA classification. Class A and Class 1 devices, which are lower-risk and follow simplified pathways anyway, are not eligible. The focus of the programme is on moderate-to-high-risk devices where registration timelines are longest and evaluation burdens are highest.

Eligibility conditions beyond device class are strict. The MDA Malaysia approval must be a full registration approval, specifically excluding devices approved under special notification pathways and devices exempted from quality, efficacy, and safety evaluation. The product as presented to Thai FDA must be identical to what was approved by MDA Malaysia: the same trade name, model identifiers, product codes, intended use, indications, labelling, accompanying documents, and packaging. Any variation between the MDA-approved version and the Thai submission disqualifies the device from the reliance route and requires the standard full submission process.

Documentation requirements are not eliminated. Manufacturers must still submit a Full CSDT dossier, formatted identically to the documents submitted to MDA Malaysia, along with evidence of the Malaysian registration. The distinction is that evaluation by an external expert panel, which has historically been a significant source of delay and uncertainty in the Thai FDA process, is removed. The documentation burden remains; the evaluation burden is substantially reduced.

Why This Matters More Than It Might Appear

For manufacturers who hold or are actively pursuing MDA Malaysia registration, the programme creates a genuine dual-market registration pathway at reduced cost and time. Thailand and Malaysia together represent a substantial share of Southeast Asia's medical device market. Registration in both historically required two full, independent regulatory processes. The reliance programme does not eliminate that requirement entirely, but it removes the most resource-intensive component of the Thai process for qualifying devices.

The ASEAN strategic context also matters. The Thai FDA's inclusion in Singapore HSA's reference authority list, alongside the US FDA, EMA, MHRA, TGA, and Health Canada, reflects a broader regional recognition of Thai FDA review quality. The MDA bilateral programme is part of the same trajectory. Thailand is positioning itself as a regional regulatory hub, not just a market. Manufacturers who build Thai FDA registration into their ASEAN market access strategy early are better positioned as that infrastructure develops further.

For manufacturers currently registered in Europe or Australia but not yet in Southeast Asia, the strategic sequencing question is now more interesting. MDA Malaysia and Thai FDA together offer a faster combined entry than either market would deliver independently through full review processes. If your pipeline includes ASEAN, the order in which you pursue registrations is worth reconsidering in light of this programme.

What to Verify Before You Apply

The most common issue that will disqualify devices from the reliance route is product variation between the MDA-approved version and the Thai submission. Manufacturers who have made any post-approval changes in Malaysia, including labelling updates, model additions, or packaging changes, need to verify that the current approved MDA version and the Thai submission are genuinely identical before applying under the reliance pathway. Submitting under reliance with a non-identical product creates a compliance problem that is more disruptive than submitting under the standard route from the start.

Confirming that your MDA approval was obtained through a full conformity assessment route, not a special notification or exemption pathway, is the second check. The programme's eligibility conditions are unambiguous on this point. If your Malaysian registration used a simplified route, the Thai reliance pathway is not available to you, and the standard process applies.

DeeMED Consulting supports foreign manufacturers with Thai FDA registration strategy and submission management, including eligibility assessment for the MDA reliance route, CSDT preparation, and local authorized representative services. If you hold MDA Malaysia registration and want to understand what a Thai FDA application looks like under this programme, contact us for an initial assessment.